This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Survey Of People Living With HIV Shows Desire For Greater Doctor-Patient Dialogue About Treatment And Disease Impact

WHITEHOUSE STATION, N.J., Sept. 9, 2013 /PRNewswire/ -- Today, results from an online nationwide survey of more than 300 people living with HIV on antiretroviral therapy show that participants are very involved in engaging with their healthcare providers in the management of their HIV; nearly all (97 percent) said that they are proactive about managing their HIV condition, including drug treatment. However, the survey findings also show that about three in four participants would like to spend more time discussing topics with their doctor about HIV drug treatment (74 percent) and the impact of HIV on their lives (71 percent) during doctor office visits.

Results of the survey, which examined the breadth and depth of communications between people living with HIV and their doctors, including level of preparation by patients for visits, content of discussions during visits and commonly used information resources, were released during the 2013 United States Conference on AIDS (USCA), the largest annual HIV gathering in the nation. The survey was conducted complementary to Merck's national HIV education campaign, I Design ( to help empower people living with HIV to have open and meaningful discussions with their doctors.

"The results of this survey are very encouraging, however they underscore the need for more in-depth discussions between people living with HIV and their doctors - not only regarding their treatment regimens, but also how the disease is affecting their lives overall," said Dr. Michael Gottlieb, Associate Clinical Professor of Medicine, David Geffen School of Medicine, UCLA. "Communication between healthcare providers and patients is the cornerstone of developing and maintaining a successful HIV treatment plan."

Key findings from the survey show that respondents are active about managing their HIV, with most indicating that they are proactive about making doctor appointments (85 percent), talking to their doctor about things that concern them (84 percent) and talking to their doctor about HIV drug treatment options (77 percent). In addition, more than half (56 percent) research HIV and HIV-related topics, and many (42 percent) talk to others living with HIV to proactively manage their HIV condition.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs